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Abstract
Background & Aims: Hepatitis B surface antigen (HBsAg) seroclearance and seroconversion are regarded as favorable
outcomes of chronic hepatitis B (CHB). This study aimed to develop artificial neural networks (ANNs) that could accurately
predict HBsAg seroclearance or seroconversion on the basis of available serum variables.
Methods: Data from 203 untreated, HBeAg-negative CHB patients with spontaneous HBsAg seroclearance (63 with HBsAg
seroconversion), and 203 age- and sex-matched HBeAg-negative controls were analyzed. ANNs and logistic regression
models (LRMs) were built and tested according to HBsAg seroclearance and seroconversion. Predictive accuracy was
assessed with area under the receiver operating characteristic curve (AUROC).
Results: Serum quantitative HBsAg (qHBsAg) and HBV DNA levels, qHBsAg and HBV DNA reduction were related to HBsAg
seroclearance (P,0.001) and were used for ANN/LRM-HBsAg seroclearance building, whereas, qHBsAg reduction was not
associated with ANN-HBsAg seroconversion (P = 0.197) and LRM-HBsAg seroconversion was solely based on qHBsAg
(P = 0.01). For HBsAg seroclearance, AUROCs of ANN were 0.96, 0.93 and 0.95 for the training, testing and genotype B
subgroups respectively. They were significantly higher than those of LRM, qHBsAg and HBV DNA (all P,0.05). Although the
performance of ANN-HBsAg seroconversion (AUROC 0.757) was inferior to that for HBsAg seroclearance, it tended to be
better than those of LRM, qHBsAg and HBV DNA.
Conclusions: ANN identifies spontaneous HBsAg seroclearance in HBeAg-negative CHB patients with better accuracy, on
the basis of easily available serum data. More useful predictors for HBsAg seroconversion are still needed to be explored in
the future.
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Introduction
In clinical practice, hepatitis B surface antigen (HBsAg)
seroclearance and seroconversion have been recommended as
the ideal outcomes in both the natural history of HBV infection
and as endpoint for the treatment of CHB [1]. Earlier HBsAg
seroclearance or seroconversion is likely resulted in a better
prognosis because of lower HBV replication as well as less liver
damage [1,2]. A few studies have explored the incidence of
spontaneous HBsAg seroclearance in CHB patients of both Asian
and European populations using long-term follow-up cohorts and
the annual incidence ranges from 0.62% to 2.26% [3,4,5,6,7,8].
Because of the more rarity of spontaneous HBsAg seroconversion,
compared to HBsAg seroclearance, the incidence and long-term
outcomes of CHB patients experiencing this event remain
disputed. Existing evidences indicate that HBsAg seroclearance
or seroconversion confers favorable long-term outcomes in
patients without hepatocellular carcinoma (HCC) or decompen-
sated liver cirrhosis [9,10,11,12].
Predictive factors for spontaneous HBsAg seroclearance or
seroconversion using various parameters have attracted much
attention recently. Previous studies had demonstrated that
lowering HBV DNA level was an important predictor for
spontaneous HBsAg seroclearance [5,6,8,13]. Furthermore, with
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the technological advances of quantitative HBsAg (qHBsAg), it has
been suggested as a promising new marker in monitoring
immunological response in both treated and untreated CHB
patients, as well as a potential predictor of liver disease progression
[14]. Our previous study showed that low qHBsAg levels and an
increased reduction rate in qHBsAg levels were the most
significant predictors of spontaneous HBsAg seroclearance with
3 years of follow-up [15]. These findings have been further
validated by other studies [4,5,13,16,17]. However, our previous
study had several limitations. No specific time point was identified
where qHBsAg kinetics could have the highest predictive value.
Also the accuracy of qHBsAg levels in predicting HBsAg
seroclearance [area under receiver operating characteristic curve
(AUROC) 0.833] still warrants improvement [15]. In all currently
available studies [4,5,13,15,16,17], the predictability of qHBsAg
levels for HBsAg seroconversion has not been thoroughly
investigated.
Being a complex biological system, the interactions among
predictors are multidimensional and non-linear, thus, making it
difficult to distinguish between classes when using the conventional
linear discriminant analysis or a single predictor. The artificial
neural network (ANN) is a novel computer model inspired by the
working of the human brain [18]. It consists of a set of highly
interconnected processing units (neurons) linked with weighted
connections, and includes an input layer, an output layer and one
or more hidden layers. The input layer is formed from the
different data available for the analysis and the output layer is
formed from the different outcomes, whereas, the hidden layers
are used to allow complex relations between the input and output
layers to evolve. One of the outstanding characteristics of the ANN
is that it can develop nonlinear statistical models to deal with
complex biological systems [19].
The main aim of the present study was to assess the ability of the
ANNs to predict HBsAg seroclearance and seroconversion in a
large population of CHB patients spontaneously clearing HBsAg
with or without the appearance of anti-HBs and compared ANNs
performance to that of conventional logistic regression models
(LRMs) as well as previously proven clinical parameters, such as
qHBsAg and HBV DNA levels.
Materials and Methods
The composition of the present study cohort has been
previously described, and is based on the comparison of CHB
patients with spontaneous HBsAg seroclearance, with age- and
sex-matched HBeAg-negative controls [15]. The present study was
a post-hoc analysis involving the entire cohort of our previous
study. In brief, all of the patients were followed up at the Liver
Clinic, Department of Medicine, the University of Hong Kong,
Queen Mary Hospital regularly for at least 3 years. All patients
had HBsAg positivity documented for more than six months and
were HBeAg-negative on presentation to our clinic. Upon their
first and/or follow-up visits, these patients had given verbal
informed consent for the storage of blood samples for further
studies.
HBsAg seroclearance or seroconversion was observed in the first
group of patients between June 2001 and February 2011; these
patients were then followed up regularly until June 2012 for their
latest liver biochemistry and HBV serology. HBsAg seroclearance
was defined as loss of serum HBsAg with or without the
appearance of antibody to HBsAg (anti-HBs), while HBsAg
seroconversion was defined as loss of serum HBsAg with the
appearance of anti-HBs. These two end-points were confirmed by
two samples taken at least six months apart. The control group,
recruited between May 2010 and May 2011, was age- and sex-
matched with the patient group achieving HBsAg seroclearance.
No treatment had been given for all of the patients during the
entire follow-up period. Serum samples collected at every visit
were stored at 220uC until tested. Serum HBV DNA and
qHBsAg levels were performed 3 years, 2 years before HBsAg
seroclearance and at time of HBsAg seroclearance (i.e., baseline).
The numbers of stored serum available for HBsAg seroclearance
or seroconversion group were 203, 190 and 203 at the time points
of 3 years, 2 years before and at the time of HBsAg seroclearance
respectively. The corresponding numbers of stored serum avail-
able for the control groups were 203, 189 and 197.
Serum qHBsAg level was measured by the Elecsys HBsAg II
assay (Roche Diagnostics, Gmbh, Mannheim, Germany) [20],
with a lower limit of detection of 0.05 IU/mL. Samples with
qHBsAg level higher than 52000 IU/mL were retested at a
dilution of 1:100, according to the manufacturer’s instructions.
Serum anti-HBs were measured by Abbott Laboratories (Chicago,
Illinois), with a lower limit of detection of 10 mIU/mL. Serum
HBV DNA level was measured using the Cobas Taqman assay
(Roche Diagnostics, Branchburg, New Jersey), with a lower limit
of detection of 20 IU/mL.
One hundred randomly chosen patients with HBsAg seroclear-
ance, followed by 100 age- and sex-matched controls, were chosen
for the determination of HBV genotype using the INNOLIPA
HBV genotyping assay, which was performed according to the
instructions of the manufacturer (Innogenetics, Gent, Belgium).
Ethics Statement
Verbal informed consent was obtained and recorded among all
patients upon their first and/or subsequent follow-up visits for the
storage of blood samples for further studies. The study was
approved by the Institutional Review Board, the University of
Hong Kong and West Cluster of Hospital Authority, Hong Kong,
including for the retrieval of archived samples for the present
study. All clinical investigation was conducted according to the
principles expressed by the Declaration of Helsinki, with all data
anonymously analyzed.
Statistical Analysis
Categorical variables were reported as the number of cases and
percentages; continuous variables were explored for parametric
distribution using the Kolmogorov-Smirnov test. For patients with
undetectable serum HBV DNA or qHBsAg, the results were taken
as the lower limit of detection (20 and 0.05 IU/mL, respectively).
As HBV DNA and qHBsAg levels showed a highly skewed
distribution, they were log transformed (log10) before the analysis.
After transformation, both variables showed a normal distribution
(P.0.05). Differences in clinical and laboratory data, related to
HBsAg seroclearance or seroconversion, were assessed using the
chi-square analysis with Yates correction and the independent-
sample T-test procedure after Levene’s test for equality of
variances, as appropriate. A subgroup analysis according to
different genotype of HBV was also performed to further test the
power of established models.
Development of the artificial neural network
Variables found to be significantly related to HBsAg seroclear-
ance or seroconversion by univariate analyses were used to build
the ANNs. Patients were randomly assigned to a training group
(70% of total patients) or a testing group (30% of total patients).
We built a three layer feed forward neural network with two
output neurons. The learning rule used here was back propagation
of errors, which adjusts the internal parameters of the network
ANN Predicts HBsAg Seroclearance
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over the repeated training cycles to reduce the overall error [21].
The weight of the connections was also altered between neurons to
decrease the overall errors of the network. Training was
terminated when the sum of square errors was at a minimum.
The activation function, representing the outcomes of ANN, was
used with continuous outputs with the interval from 0 to 1, in
which 0=HBsAg non-seroclearance/non-seroconversion,
1 =HBsAg seroclearance/seroconversion. The cut-offs of ANN
outputs with the best relationship between sensitivity and
specificity were used for classification. The relative weights of
the input variables for the ANNs were calculated according to the
General Influence Measure method [22]. In this study, we built
ANNs by using the graphical neural network development tool
NeuroSolution V5.05 (Neurodimension, Gainesville, FL, USA).
Development of the multivariate logistic regression
model
In the training group (70% of total patients), variables found to
be significantly related to HBsAg seroclearance or seroconversion
by univariate analysis entered into two distinct forward conditional
multivariate logistic regression models (LRMs). Logistic regression
generated the coefficients of a formula to predict a logit
transformation of the probability of presence of the characteristic
of interest: logit(p) = b0 + b1x1 + b2x2 +… + bkxk. The probability
of presence of the characteristic of interest was obtained by the
formula p=1/(1+e2logit(p)) in which 0=HBsAg non-seroclear-
ance/non-seroconversion, 1=HBsAg seroclearance/seroconver-
sion. The cut-offs of logistic regression outputs with the best
relationship between sensitivity and specificity were adopted for
classification.
Assessment of the diagnostic accuracy
The performances of both ANNs and LRMs, as well as qHBsAg
and HBV DNA levels, in predicting HBsAg seroclearance or
seroconversion in the training group and in three validation
groups (testing group, genotype B group, genotype C group) were
tested using receiver operating characteristic (ROC) curve analysis
and expressed in terms of sensitivity, specificity, positive predictive
values (PPV) and likelihood ratios (LR). Youden index was
calculated to discriminate the optimal cut-off value. Comparison
of ROC curves was obtained using the Hanley-McNeil method
[23].
A two-sided P value of,0.05 was considered statistically
significant. Statistical analysis and ROC analysis were computed
by MedCalc 10.0 software (Mariakerke, Belgium) and SPSS 18.0
software (SPSS Inc, Chicago, IL, USA).
Results
Baseline Characteristic of Patients
Baseline characteristic of the entire study population were
outlined in Table 1. The mean age was 48.8610.9 years and
patients were predominantly male (70.4%). 63 patients (31.0%) in
the HBsAg seroclearance group had developed anti-HBs. There
were no significant differences in the distribution of age, gender,
alanine aminotransferase (ALT) level, bilirubin and genotype
when comparing patients with HBsAg seroclearance with and
without seroconversion (all P.0.05). Patients with HBsAg
seroclearance or seroconversion had significantly lower serum
qHBsAg, HBV DNA levels at baseline (all P,0.001), compared to
controls as previously described.[15] Specific characteristics of
four groups/subgroups (including training, testing, genotype B and
genotype C) were outlined in Table 2, Table S1–S5. There were
Table 1. Baseline characteristics of the study population.
Variables
All patients
(n=406)
HBsAg seroclearance patients
(n=203)
Control cohort
(n =203) P
Time point 0 year (baseline)
Age (years) 48.8610.9 48.7611.1 49.0610.7 0.791
Male gender (%) 286 (70.4) 143 (70.4) 143 (70.4) 0.999
ALT (IU/L) 27.5616.8 28.6619.8 26.5613.0 0.208
Bilirubin (mmol/L) 13.568.8 13.7610.8 13.366.2 0.706
Genotype1 (%)
B 141 (72.7) 59 (64.8) 82 (79.6) 0.244
C 53 (27.3) 32 (35.2) 21 (20.4)
qHBsAg (log10 IU/ml) 0.5262.02 21.3060.00 2.3561.20 0.001
HBV DNA (log10 IU/ml) 2.3861.46 1.3760.23 3.4061.47 0.001
Time point 2 years
qHBsAg (log10 IU/ml) 1.5961.45 0.5660.93 2.6061.12 0.001
HBV DNA (log10 IU/ml) 2.6361.35 1.8360.75 3.4261.35 0.001
Time point 3 to 2 years
qHBsAg reduction (log10 IU/ml) 0.4160.55 0.6660.60 0.1660.36 0.001
HBV DNA reduction (log10 IU/ml) 0.1860.97 0.4060.86 20.0561.01 0.001
Time point 3 years
qHBsAg (log10 IU/ml) 1.9961.33 1.2661.11 2.7261.10 0.001
HBV DNA (log10 IU/ml) 2.7961.28 2.2560.97 3.3361.32 0.001
1Tested in 200 patients (194 had amplificable polymerase chain reaction products). Time point is defined as the period before HBsAg seroclearance: 0 year indicates
date of seroclearance (baseline).
doi:10.1371/journal.pone.0099422.t001
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no significant differences in the distribution of age, gender, ALT,
bilirubin, qHBsAg level, HBV DNA, qHBsAg reduction, HBV
DNA reduction between the training group with the other three
testing groups (all P.0.05).
Development of the ANNs and LRMs
With respect to HBsAg seroclearance, in the training
group of 284 (70% 6 406) patients, qHBsAg level
(OR=0.327, 95%CI= 0.261–0.411, P,0.001), HBV DNA
(OR=0.449, 95%CI= 0.367–0.548, P,0.001), qHBsAg reduc-
tion (OR=12.763, 95%CI=6.575–24.773, P,0.001), and HBV
DNA reduction (OR=1.738, 95%CI= 1.356–2.227, P,0.001)
were significantly associated with HBsAg seroclearance by
univariate analysis (Table 3). With respect to HBsAg seroconver-
sion, in the training group of 137 (70%6 203) patients, qHBsAg
level (OR=1.474, 95%CI= 1.112–1.953, P= 0.007), HBV DNA
(OR=1.416, 95%CI=1.045–1.919, P= 0.025), and HBV DNA
reduction (OR=1.459, 95%CI=1.011–2.107, P = 0.044) were
significantly associated with HBsAg seroconversion by univariate
analysis (Table 3). These variables were used to build the ANNs,
respectively (Figure 1A and 1B). All variables had a significant
contribution in predicting HBsAg seroclearance or seroconversion
and the removal of any one of them diminished the performance
of the ANNs (Figure 2).
The multivariate LRM confirmed qHBsAg level
(OR=0.316, 95%CI= 0.227–0.439, P,0.001), HBV DNA
(OR=0.473, 95%CI= 0.325–0.687, P,0.001), qHBsAg reduc-
tion (OR=18.802, 95%CI=7.919–44.641, P,0.001), and HBV
DNA reduction (OR=2.306, 95%CI= 1.453–3.662, P,0.001) as
independent predictors for HBsAg seroclearance (284 patients);
qHBsAg level (OR=1.472, 95%CI= 1.097–1.975, P= 0.01) as
independent predictors for HBsAg seroconversion (137 patients),
and were used to build the LRMs, respectively (Table 3).
Assessment of the predictive accuracy of ANNs
compared with LRMs/parameters
The performance of the ANN in predicting HBsAg seroclear-
ance in this group was very high, with AUROC of 0.957
(95%CI=0.924–0.978). It was significantly higher compared to
that of the LRM, qHBsAg level and HBV DNA (AUROC 0.930,
95%CI=0.892–0.958, P= 0.047; 0.847, 95%CI=0.797–0.889,
P,0.001; 0.768, 95%CI=0.711–0.818, P,0.001 respectively)
(Figure 3A, Table 4). Although the AUROC of the ANN in
predicting HBsAg seroconversion was lower than that for HBsAg
seroclearance, the performance of the ANN in predicting HBsAg
seroconversion was still better than the LRM, qHBsAg level and
HBV DNA. It was 0.757 (95%CI= 0.672–0.829) which was still
significantly higher than that of HBV DNA (AUROC 0.604,
95%CI=0.513–0.690; P= 0.013), and showed a trend to be better
than those of LRM and qHBsAg level (AUROC 0.670,
95%CI=0.581–0.751, P= 0.063; 0.670, 95%CI=0.581–0.751,
P= 0.063 respectively) (Table 4). With a cut-off value of 0.474,
ANN-HBsAg seroclearance had an excellent sensitivity of 94.7%
and specificity of 82.6% (Table 5, data of ANN-HBsAg
seroconversion not shown).
Validation in testing group
When the ANNs were evaluated in the testing group, the
performance of the ANN in predicting HBsAg seroclearance was
very high, with AUROC of 0.929 (95%CI= 0.862–0.969) which
Table 2. Characteristics of the study population stratified by ANN groups.
Variables Training group Testing group P
Age (years) HBsAg seroclearance 48.4610.8 49.7611.0 0.288
HBsAg seroconversion 48.3610.5 49.4612.3 0.536
Male gender (%) HBsAg seroclearance 200 (70.4) 86 (70.5) 0.989
HBsAg seroconversion 97 (70.8) 46 (69.7) 0.871
ALT (IU/L) HBsAg seroclearance 28.0617.4 26.3615.2 0.356
HBsAg seroconversion 29.3619.2 27.0621.2 0.445
Bilirubin (mmol/L) HBsAg seroclearance 13.669.2 13.267.7 0.674
HBsAg seroconversion 12.668.7 16.0613.9 0.072
qHBsAg (log10 IU/ml)* HBsAg seroclearance 1.9461.33 2.1361.31 0.190
HBsAg seroconversion 1.2261.13 1.3561.09 0.452
HBV DNA (log10 IU/ml)* HBsAg seroclearance 2.7461.21 2.9161.41 0.241
HBsAg seroconversion 2.2360.91 2.3061.10 0.671
qHBsAg (log10 IU/ml)1 HBsAg seroclearance 1.5361.43 1.7261.50 0.250
HBsAg seroconversion 0.5760.96 0.5460.88 0.847
HBV DNA (log10 IU/ml)1 HBsAg seroclearance 2.5361.28 2.8661.49 0.028
HBsAg seroconversion 1.7960.71 1.9360.83 0.247
qHBsAg reduction (log10 IU/ml)" HBsAg seroclearance 0.4060.52 0.4260.62 0.816
HBsAg seroconversion 0.6260.59 0.7460.60 0.218
HBV DNA reduction (log10 IU/ml)" HBsAg seroclearance 0.2260.94 0.0861.03 0.219
HBsAg seroconversion 0.4360.84 0.3560.90 0.542
The number in training group was 284 patients related to HBsAg seroclearance and 137 patients related to HBsAg seroconversion, while in testing group was 122
patients related to HBsAg seroclearance and 66 patients related to HBsAg seroconversion. *Time point 3 years. 1Time point 2 years. "Time point 3 to 2 years. Time point
is defined as the period before HBsAg seroclearance: 0 year indicates date of seroclearance (baseline).
doi:10.1371/journal.pone.0099422.t002
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was significantly higher than qHBsAg level and HBV DNA
(AUROC 0.838, 95%CI= 0.757–0.901, P= 0.030; 0.727,
95%CI= 0.635–0.807, P,0.001). It was comparable to that of
the LRM (AUROC 0.953, 95%CI= 0.895–0.984; P= 0.310)
(Figure 3B, Table 4). The performance of the ANN in predicting
HBsAg seroconversion was not satisfactory, with an AUROC of
0.626 (95%CI= 0.494–0.746). It was not significantly better when
compared to that of the LRM, qHBsAg level and HBV DNA
(AUROC 0.556, 95%CI= 0.424–0.682, P= 0.308; 0.556,
95%CI=0.424–0.682, P= 0.308; 0.549, 95%CI=0.418–0.676,
P= 0.311) (Table 4).
Validation in the subgroup of genotype B and C
The performance of the ANN in predicting HBsAg seroclear-
ance in genotype B subgroup (141 patients) was very high, with
AUROC of 0.953 (95%CI= 0.899–0.983) significantly higher
than qHBsAg level and HBV DNA (AUROC 0.788,
95%CI=0.706–0.856, P,0.001; 0.698, 95%CI=0.609–0.777,
Figure 1. Schematic representation of the artificial neural network developed to predict A) HBsAg seroclearance and B) HBsAg
seroconversion. Note: qHBsAg, 3 years before baseline; HBV DNA, 3 years before baseline; qHBsAg reduction, 3 to 2 years before baseline; HBV DNA
reduction, 3 to 2 years before baseline.
doi:10.1371/journal.pone.0099422.g001
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P,0.001). It was comparable to that of the LRM (AUROC 0.926,
95%CI= 0.865–0.965; P = 0.142) (Figure 3C, Table 4). In
genotype C subgroup (53 patients), the performance of the ANN
in predicting HBsAg seroclearance was higher than LRM,
qHBsAg level and HBV DNA. However, it did not draw a
statistically significance among them (P= 0.396, P = 0.054,
P = 0.139, respectively) (Figure 3D, Table 4). Similarity, the
performance of the ANN in predicting HBsAg seroconversion in
genotype B and C subgroups (59 and 32 patients, respectively) was
not satisfactory, with an AUROC of 0.784 (95%CI=0.649–0.885)
and 0.529 (95%CI=0.336–0.716), respectively, not significantly
higher than that of the LRM, qHBsAg level and HBV DNA
(P=0.055, P= 0.055, P= 0.053, respectively; P= 0.846, P = 0.846,
P = 0.441, respectively) (Table 4).
Discussion
HBsAg seroclearance and seroconversion are accepted world-
wide as the two most powerful indictors of prognosis in CHB
patients, as shown by many studies investigating these topics
[2,9,10,11,12,24]. Prejudging or predicting of these features to
untreated or treated CHB patients are therefore, highly desirable,
as they could help hepatologists in providing optimal therapeutic
regimen [1].
In recent years, ANN modeling has been increasingly used in
clinical management and disease prognostication, including in the
prediction of disease-free survival in HCC patients [25], assessing
preoperative HCC grading and micro-vascular invasion [26], and
predicting the mortality risk of patients with end-stage liver disease
or acute-on-chronic hepatitis B liver failure [27,28]. Due to the
three main advantages of ANN, namely self-learning, self-adapting
and inference process, the ANN model has been demonstrated to
perform better than conventional discriminant analysis in precisely
predicting disease outcomes [19]. To date, the complex interaction
of the different variables that can be obtained during the natural
history of CHB, has not led to any predictive model able to
recognize HBsAg seroclearance or seroconversion with sufficient
accuracy to be usefully employed as an easy-to-use tool in the
clinical setting. In the present study, the ANN was found to be
superior to linear discriminant analysis as well as qHBsAg and
HBV DNA levels both in the training group and non-inferior to
linear discriminant analysis in the testing group, and very reliable
in identifying HBsAg seroclearance. The better performance of
ANN supported the postulation that HBsAg seroclearance was a
complex, multidimensional nonlinear function [18,19]. Our model
was able to give a more precise estimate of HBsAg seroclearance
on the basis of serum-based data routinely available in the clinical
setting.
Our previous study showed low qHBsAg levels and increased
rate of qHBsAg decline could predict HBsAg seroclearance [15].
By selecting these two clinical parameters and entering them into
building the ANN and LRM, the accuracy of low qHBsAg in
predicting HBsAg seroclearance was further increased (AUROC
0.847, 95%CI= 0.797–0.889). Accompanied with qHBsAg level
decreasing gradually over times, lower levels of qHBsAg or rapid
reduction rate of qHBsAg would eventually lead to HBsAg
seroclearance or seroconversion [16]. Another important finding
was the HBV DNA level and their reductions, which had
Figure 2. Relative weights of the clinical input parameters in an artificial neural network (ANN) trained with patients of training set.
(A) ANN for HBsAg seroclearance; (B) ANN for HBsAg seroconversion. Note: qHBsAg, 3 years before baseline; HBV DNA, 3 years before baseline;
qHBsAg reduction, 3 to 2 years before baseline; HBV DNA reduction, 3 to 2 years before baseline.
doi:10.1371/journal.pone.0099422.g002
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previously been considered as powerful predictors for HBsAg
seroclearance in pre-qHBsAg era [6,8]. Liu et al. found that
decrease in HBV DNA levels was the most important predictor of
HBsAg seroclearance [8]. However, the predictability of HBsAg
seroclearance increased greatly when they added the qHBsAg level
into consideration [13]. In the present study, we compared the
combination of the above predictors (ANN and LRM), as well as
the separate predictors (qHBsAg and HBV DNA), respectively.
Figure 3. ROC analysis displaying the ability of four models/parameters (ANN, LRM, qHBsAg* and HBV DNA*) to discriminate
HBsAg seroclearance in (A) training group; (B) testing group; (C) genotype B subgroup; (D) genotype C subgroup. *Time point 3 years;
LRM, logistic regression model; ANN, artificial neural network.
doi:10.1371/journal.pone.0099422.g003
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Under these circumstances, use of the present ANN for HBsAg
seroclearance, except for ANN for HBsAg seroconversion, could
lead to an improvement in diagnostic accuracy and in tailoring the
best individual clinical management.
The ANN for HBsAg seroconversion (AUROC 0.757) was
inferior to that for HBsAg seroclearance. One of the potential
reasons was the relatively small sample size (n = 63) which could
affect the performance of ANN [22]. Nonetheless, given the rarity
of HBsAg seroconversion, it would be difficult to recruit more
subjects for a more thorough analysis. Another important reason
was due to the lacking of significant predictors besides of the
currently-available qHBsAg [24]. A good model for predicting
HBsAg seroconversion remains to be discovered. Similarity, in
genotype C subgroup, the performance of the ANN in predicting
HBsAg seroclearance was not statistically significant and possibly
underpowered since genotype C only comprised approximately
one-third of the total patient cohort. A validation study
concentrating on genotype C patients could be considered in the
future.
Our study was limited by ANN being built and tested on a
single center cohort, and it could thus be argued that data
originating from other centers might lead to different conclusions.
However, we believe that this should not be considered as a
shortcoming since the distinctive characteristic of the ANN is that
it can learn through examples making the prediction of HBsAg
seroclearance, even in HBsAg seroconversion, feasible on datasets
from other sources.
In conclusion, ANN could accurately predict spontaneous
HBsAg seroclearance in HBeAg-negative CHB patients, on the
basis of easily available serum data within a shorter period of no
more than 3 years. ANN for HBsAg seroclearance was superior to
the conventional statistical linear approach and it could be used in
predicting the outcome of CHB. The performance of ANN for
HBsAg seroclearance can be further improved by including new
cases from other centers due to the unique ability of learning of
neural networks.
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